CodaVax™ RSV Vaccine Description

Codagenix is utilizing codon-deoptimized live vaccine candidates to deliver all the benefits of live vaccines on short timelines while offering unparalleled genetic stability.

Codagenix's “death by a thousand cuts” approach takes the genetic sequence of the wild-type target and uses an AI-aided algorithm to compute the hundreds or thousands of sites where codons can be modified to produce the same amino acid sequence with lower translational efficiency. This process yields a small, testable number of candidate viral genomes that produce all the same proteins as the wild type but with far less virulence, exponentially accelerating timelines for candidate development.

Therefore, unlike previous live-attenuated RSV vaccine candidates, CodaVax-RSV is extremely stable due to genetic edits that prevent wild-type reversion. 

CodaVax RSV Vaccine Price

As of November 2022, the price for the CodaVax vaccine candidate was not announced. The U.S. CDC Vaccine Price List was updated on September 2022. Additional vaccine price and discount information is posted at InstantRx™.

CodaVax Indication

CodaVax is indicated to prevent RSV infections in infants and adults.

CodaVax News 2022

November 2, 2022 - The US FDA has granted Codagenix Fast Track Designation for CodaVax-RSV, an intranasal RSV vaccine candidate. 

CodaVax Clinical Trials

CodaVax has completed a phase 1 clinical trial and will begin recruiting for another phase 1 trial.

The first phase 1 clinical trial has been completed: Safety and Immunogenicity of a Live-attenuated Vaccine Against Respiratory Syncytial Virus in Elderly Volunteers.  This trial began on July 10, 2020, enrolling 36 healthy adult volunteers. The participants received two doses, 28 days apart. The vaccine was administered as nose drops.

The second phase 1 study has yet to start recruiting.  It will be a study to analyze the Safety and Immunogenicity of CodaVax-RSV in Seropositive and Seronegative Children.